Loading organizations...
§ Private Profile · Daxing, Beijing, China
Global biotechnology company providing integrated solutions for antibody drug discovery and development using genetically engineered animal models.
Beijing-based Biocytogen, with major operations in Massachusetts and Germany, is a global biotechnology company that provides integrated solutions for antibody drug discovery and preclinical validation using proprietary genetically engineered animal models. The publicly traded firm operates a commercial model that generates revenue through licensing proprietary antibody assets, selling specialized animal models, and providing fee-for-service preclinical research and custom gene-editing services. Listed on the Hong Kong Stock Exchange, the enterprise maintains a global workforce of over 1,300 employees and reported an annual revenue of approximately RMB 717 million in 2023. The company collaborates with over 70 percent of the top 50 global pharmaceutical firms, maintaining notable partnerships and licensing agreements with BioNTech, Gilead Sciences, Merck KGaA, and Neurocrine Biosciences. The biotechnology corporation Biocytogen was originally founded in Massachusetts in 2008 by Dr. Yuelei Shen.
Biocytogen has raised $142.0M across 1 funding round.
Biocytogen has raised $142.0M in total across 1 funding round.
Biocytogen has raised $142.0M in total across 1 funding round.
Biocytogen's investors include CMB International, 3E Bioventures Capital, CDH Investments, Guotou Chuangye.
Biocytogen has raised $142.0M across 1 funding round. Most recently, it raised $142.0M Series D in September 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 25, 2020 | $142M Series D | CMB International | 3E Bioventures Capital, CDH Investments, Guotou Chuangye | Announced |